The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INMB | -66.05% | -76.41% | -25.09% | -77% |
| S&P | +18.37% | +110.18% | +16.02% | +152% |
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $53.62M | -69.3% |
| Market Cap / Employee | $2.44M | 0.0% |
| Employees | 22 | 29.4% |
| Net Income | -$24.46M | -151.0% |
| EBITDA | -$8.06M | 18.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $33.37M | 7.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.23M | -28.3% |
| Short Term Debt | $0.22M | -95.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -123.16% | -61.4% |
| Return On Invested Capital | -61.95% | -19.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.08M | -2.5% |
| Operating Free Cash Flow | -$7.38M | 6.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.86 | 2.68 | 5.42 | 1.79 | -67.28% |
| Price to Sales | 2590.50 | 7432.12 | 3513.91 | 1076.39 | -46.27% |
| Price to Tangible Book Value | 5.16 | 4.67 | 11.17 | 4.03 | -68.20% |
| Enterprise Value to EBITDA | -6.36 | -8.82 | -15.82 | -2.59 | -82.31% |
| Return on Equity | -99.0% | -119.8% | -139.0% | -168.3% | 95.66% |
| Total Debt | $2.91M | $0.38M | $0.35M | $0.45M | -91.70% |
INMB earnings call for the period ending June 30, 2022.
INMB earnings call for the period ending March 31, 2022.
INMB earnings call for the period ending December 31, 2021.
INMB earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
